CORMEDIX INC (CRMD)
Health Care · specialty pharmaceuticals · NASDAQ
A commercial-stage biopharmaceutical company focused on preventing catheter-related bloodstream infections and delivering a portfolio of hospital-based anti-infective therapies.
What CORMEDIX INC does
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, particularly in the hospital and infectious disease settings. Its lead product is DefenCath, an FDA-approved antimicrobial and anticoagulant catheter lock solution indicated to reduce catheter-related bloodstream infections in hemodialysis patients. Following the acquisition of Melinta Therapeutics, the company also markets a portfolio of hospital-focused infectious disease anti-infectives and a cardiovascular medication.
Recent developments
CorMedix reported positive Phase III results for REZZAYO in prophylaxis for invasive fungal diseases and anticipates filing an sNDA in Q3 2026. The company also signed a new supply agreement for DefenCath that covers all top 5 U.S. dialysis providers and raised its full-year 2026 adjusted EBITDA guidance.
From CORMEDIX INC's filing of 2026-08-13.
Themes: infectious disease, hemodialysis / renal care, catheter-related bloodstream infections, hospital-based care, anti-infectives / antibiotics, fungal infection prophylaxis
Fundamentals
- Price$7.57 as of 2026-10-20 close
- Market cap$590M as of 2026-08-10 (share count; price 2026-10-20)
- 1-year return-37.7% 2025-10-20 close $12.16 → 2026-10-20 close $7.57
- P/E3.47 as of 2026-10-20
- Net margin+52.3% FY2025, SEC XBRL
- Gross margin+88.5% FY2025, SEC XBRL
- ROE+40.2% FY2025, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+617.0% FY2025, SEC XBRL
- Revenue CAGR (3y)+535.6% SEC XBRL
- Beta0.79 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CRMD compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 10% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | — | $77M | $43M | $26M | $0.29 | $86M† | $561000† |
| Q1 FY2026 2026-03-31 | — | $105M | $64M | $39M | $0.43 | $42M | $729000 |
| Q4 FY2025 2025-12-31 | $129M† | $107M† | $59M† | $14M† | $0.07† | $94M† | $2M† |
| Q3 FY2025 2025-09-30 | $104M | $93M | $51M | $109M | $1.26 | $31M† | $505896† |
| Q2 FY2025 2025-06-30 | $40M | $38M | $20M | $20M | $0.28 | $30M† | $24000† |
| Q1 FY2025 2025-03-31 | $39M | $37M | $20M | $21M | $0.30 | $20M | $10000 |
| Q4 FY2024 2024-12-31 | $31M† | $30M† | $13M† | $13M† | $0.24† | -$6M† | $10139† |
| Q3 FY2024 2024-09-30 | $11M | $11M | -$3M | -$3M | -$0.05 | -$14M† | $9766† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$257M
- Short-term investments$0
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How CORMEDIX INC looks technically
CORMEDIX INC (CRMD) is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 13 trading days ago. It is 41.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend | -2.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.83 | $7.83 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.77 | $7.77 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 8.06. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($7.06 to $7.70) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.02 | $13.02 |
|---|---|---|
| From the 52-week high | it is 41.9% below its 52-week high (its highest price of the past year) | -41.9% |
| Above the 52-week low | it is 23.6% above its 52-week low (its lowest price of the past year) | +23.6% |
| Below the 52-week high | it is 41.9% below its highest point of the past year | 41.9% |
| Since a 20-day breakout | it made a new 20-day low about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $52.00 (set on 2015-04-01) | $52.00 |
| Given back of the 52-week move | over the past year its closes ranged ($6.25 to $12.73), and it has recovered roughly a quarter of its fall from last year’s high — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.25 to $10.46. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 20.4% |
| From the all-time high | it is 85.4% below its all-time high | -85.4% |
| Nearest price level | it is trading 1.4% above a support level at $7.47 — a price it turned at twice since 2026-02-26, most recently on 2026-06-29. Since 2024-10-21 it has 3 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $0.7285 (set on 2012-06-15) | $0.7285 |
| Above the all-time low | it is 939.1% above its all-time low | +939.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 87% of it) | 13th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2603 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2603 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.04 and $7.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.04 – $7.49 – $7.94 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (2.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-09-23 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.27% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.9 percentage points (the stock lost 1.9% while the market gained 1.0%) | -2.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 6.3 percentage points (the stock lost 2.7% while the market gained 3.6%) | -6.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.6 percentage points (the stock lost 0.1% while the market gained 8.5%) | -8.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 52.3 percentage points (the stock lost 37.7% while the market gained 14.6%) | -52.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | -5.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.72 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -2.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $7.85 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -3.6% |
Double top, bearish — forming · entry $7.10 · 74 sessions in
Double bottom, bullish — forming · entry $8.61 · 48 sessions in
Price levels it has turned at before
CRMD last closed at $7.57 on 2026-10-20. Since 2024-10-21 it has turned at 3 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.47 | Support | 1.4% below the last close | turned there twice · 2026-02-26 to 2026-06-29 |
| $7.75 | Resistance | 2.4% above the last close | turned there twice · 2024-12-31 to 2025-04-08 |
| $8.05 | Resistance | 6.4% above the last close | turned there three times · 2024-12-18 to 2026-08-31 |
| $7.08 | Support | 6.4% below the last close | turned there four times · 2026-04-17 to 2026-10-05 |
| $8.73 | Resistance | 15.4% above the last close | turned there twice · 2025-05-05 to 2026-09-03 |
| $6.14 | Support | 18.8% below the last close | turned there twice · 2026-03-06 to 2026-03-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $8.06.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.46 and $7.91 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $7.06.
This reading has stood for 7 trading days, since 2026-10-12.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$15.33 range $13.00 – $19.00; median $15.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Dependence on the successful commercial adoption and reimbursement of DefenCath, including changes in CMS payment methodologies.","Risks associated with integrating the Melinta acquisition and managing the expanded commercial portfolio.","Potential for supply chain disruptions and margin pressures from new tariffs on imported pharmaceutical components."]
What changed in the latest 10-Q
AI-assisted comparison of CRMD's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Added a new paragraph in Recent Developments stating that on June 8, 2026, the United States Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.
- Reworded:
- Changed the sentence about DefenCath TDAPA reimbursement from 'On July 1, 2026, DefenCath’s TDAPA reimbursement transitions into a post-TDAPA Add-On Adjustment, the calculation of which is determined by CMS. As a result of the methodology utilized by CMS, the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, CorMedix expects a corresponding reduction to its net pricing for DefenCat' in the older filing to 'On July 1, 2026, DefenCath’s TDAPA reimbursement transitioned into a post-TDAPA Add-On ' in the newer filing, with the newer sentence appearing truncated.
- Notes:
- The newer MD&A text appears to be cut off mid-sentence in the Results of Operations section, limiting comparison of the full TDAPA reimbursement discussion.
- Page number changed from 23 in the older filing to 26 in the newer filing, reflecting a formatting or pagination change only.
Risk Factors
- Added:
- Exhibits 10.1 and 10.2 in the newer filing (filed 2026-08-13) are a License Agreement dated July 26, 2022 between Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. and Amendment No. 1 to that License Agreement dated April 23, 2024, both noted as having portions omitted in reliance on Item 601(b)(10)(iv) of Regulation S-K.
- In the newer filing (filed 2026-08-13), the share repurchase table covers Q2 2026 (April through June 2026) and shows 814,281 total shares repurchased with a maximum remaining repurchase amount of $57,516,000.
- Removed:
- In the older filing (filed 2026-05-14), Item 5 disclosed that on May 12, 2026 the Company entered into amended and restated executive employment agreements with Susan Blum, Elizabeth Hurlburt, and Beth Zelnick Kaufman, including details of base salaries, bonus targets, and severance benefits.
- Exhibits 10.1, 10.2, and 10.3 in the older filing (filed 2026-05-14) are the Amended and Restated Executive Employment Agreements dated May 12, 2026 for Susan Blum, Elizabeth Hurlburt, and Beth Zelnick Kaufman, marked as management contracts or compensation plans.
- In the older filing (filed 2026-05-14), the share repurchase table covers Q1 2026 (January through March 2026) and shows 1,589,071 total shares repurchased with a maximum remaining repurchase amount of $63,908,000.
- Reworded:
- Item 5 in the older filing (filed 2026-05-14) contains a paragraph about amended and restated executive employment agreements dated May 12, 2026; in the newer filing (filed 2026-08-13), that paragraph is absent and Item 5 consists only of the Rule 10b5-1 trading arrangement disclosure, updated to reference the three months ended June 30, 2026 instead of March 31, 2026.
- The exhibit index changed between filings: the older filing (filed 2026-05-14) lists exhibits 10.1, 10.2, and 10.3 as Amended and Restated Executive Employment Agreements; the newer filing (filed 2026-08-13) lists exhibits 10.1 and 10.2 as a License Agreement and Amendment between Melinta Therapeutics, LLC and Cidara Therapeutics, Inc.
- Notes:
- The section labeled 'Risk Factors' in both filings contains identical risk factor text; the comparative differences arise in adjacent sections (Items 2, 5, and 6) that were included in the provided excerpts. No changes were identified in the Risk Factors paragraph itself.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CRMD — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CRMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,363,758
- Reported value $73,505,500
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CRMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CRMD had 15,422,728 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
CRMD had 19.8% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.9 days to cover at the same settlement.
- Reported short interest (shares) 15,422,728
- Short interest (% of shares outstanding) 19.8%
- Prior settlement (shares) 16,202,272
- Reported change -4.81%
- Days to cover (reported) 18.9
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Merck (MRK)
- Baxter International (BAX)
- B. Braun Medical
- Fresenius Medical Care (FMS)
- Cidara Therapeutics (CDTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRMD vs…
CRMD ranks in…
Frequently asked questions
What does CORMEDIX INC (CRMD) do?
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, particularly in the hospital and infectious disease settings. Its lead product is DefenCath, an FDA-approved antimicrobial and anticoagulant catheter lock solution indicated to reduce catheter-related bloodstream infections in hemodialysis patients.
What sector is CORMEDIX INC (CRMD) in?
CORMEDIX INC (CRMD) is classified in the Health Care sector. Its industry is specialty pharmaceuticals. It trades on NASDAQ.
Who are CORMEDIX INC's (CRMD) competitors?
Notable peers of CORMEDIX INC (CRMD) include Pfizer, Merck, Baxter International, B. Braun Medical and Fresenius Medical Care. This peer set is informational only — not financial advice.
Is CORMEDIX INC (CRMD) overbought or oversold right now?
CORMEDIX INC (CRMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.